Physician profile
Preetesh Jain
NPI 1578981221
$84,491.69
in general payments reported to CMS, 2019-2025
14 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.16 · 2020: $3,450 · 2021: $6,565 · 2022: $14K · 2023: $13K · 2024: $16K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Travel and Lodging: $2,089 · Food and Beverage: $1,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,815.00 |
| Travel and Lodging | $2,088.81 |
| Food and Beverage | $1,974.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40,432.69 | 2022-2025 | Jaypirca |
| Astrazeneca Pharmaceuticals LP | $21,434.14 | 2022-2025 | Calquence, Lumoxiti |
| Eli Lilly and Company | $9,062.50 | 2020-2024 | Jaypirca |
| Astrazeneca Uk Limited | $3,535.35 | 2023 | Calquence |
| Kite Pharma, INC. | $2,441.16 | 2019-2021 | |
| Incyte Corporation | $2,152.50 | 2021 | |
| Chugai Pharmaceutical Co., LTD. | $1,773.33 | 2022 | |
| Beone Medicines USA, INC. | $1,692.42 | 2025 | Brukinsa |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $281.12 | 2023-2025 | Clonoseq |
| Beigene USA, INC. | $171.48 | 2023 | Brukinsa |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preetesh Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.